World Trademark Review Recognizes Foley Attorneys and Offices in 2021 Edition of WTR 1000: The World’s Leading Trademark Practitioners
11 February 2021
Eight Foley attorneys and three Foley offices have been named in the 2021 edition of the World Trademark Review 1000: The World’s Leading Trademark Practitioners. The WTR 1000 directory is compiled by a team of researchers based on more than 1,700 interviews with trademark practitioners and corporate counsel regarding services provided in areas such as prosecution and strategy and enforcement and litigation.
The Foley attorneys recognized include:
- Katherine Califa (prosecution and strategy)
- Mark Diliberti
- Laura Ganoza
- Jami Gekas (prosecution and strategy, enforcement and litigation)
- Rick McKenna
- Jonathan Moskin (enforcement and litigation)
- Norm Rich (prosecution and strategy)
- Robert Weisbein (prosecution and strategy, enforcement and litigation)
The Foley offices recognized include:
- District of Columbia (prosecution and strategy)
- Milwaukee
- New York (prosecution and strategy, enforcement and litigation)
For more information about WTR, please visit their website here.
People
Related News
25 July 2024
In the News
Donald Schroeder on Groff – ‘Supreme Court decision is inviting a more fact-based analysis’
Foley & Lardner LLP partner Donald Schroeder assessed the impact of the U.S. Supreme Court’s 2023 decision in a religious accommodation case as it returns to the district court in the Law360 article, “A Year After High Court Spotlight, Groff Case Still A Bellwether.”
24 July 2024
In the News
Louis Lehot Featured in Q&A on How Startups Can Prepare for IPO
Foley & Lardner LLP partner Louis Lehot features in the Q&A, "How startups can get in top shape for an IPO, according to Silicon Valley lawyer Louis Lehot," part of Business Insider's Road to IPO' series.
24 July 2024
In the News
Courtenay Brinckerhoff on Patent Cap in Drug Pricing – ‘Hard to predict if this will make a difference’
Foley & Lardner LLP partner Courtenay Brinckerhoff discussed a recent bill passed in the U.S. Senate aimed at lowering drug prices by limiting the number of patents that can be asserted in cases over biosimilars in the Law360 article, “Patent Cap In Drug Pricing Bill Seen As Having Muted Effect.”